Joint Health, Inflammation, and Exercise Recovery

Evidence Review

Osteoarthritis: The Core Evidence

Kim et al. 2006 (PMID 16309928) is the landmark pilot trial establishing MSM's role in osteoarthritis. Fifty adults aged 40–76 with knee OA pain were randomized to MSM 3 g twice daily (6 g/day total) or placebo for 12 weeks in a double-blind, placebo-controlled design. The MSM group showed statistically significant improvements in WOMAC pain subscale scores (p < 0.05) and physical function scores compared to placebo. No significant changes were seen in stiffness subscores. The study also assessed safety through lab work and vital signs and found no clinically meaningful adverse events. As a pilot trial with 50 participants, the sample size limits generalizability, but the clean design and objective outcome measures made this a credible foundation for subsequent work.

Debbi et al. 2011 (PMID 21708034) followed with a larger trial enrolling 49 adults aged 45–90 with knee OA. Participants received MSM 1.125 g three times daily (3.375 g/day) or matched placebo for 12 weeks. WOMAC pain and function improved in the MSM group versus placebo, and both the Aggregated Locomotor Function (ALF) test and SF-36 quality-of-life scores trended better in the treatment arm. However, the authors noted that while statistically significant improvements were observed, the effect sizes were modest and the clinical meaningfulness — whether the changes are large enough for patients to notice in daily life — remains open to discussion. This is an important point: MSM is unlikely to replace pharmaceutical pain management in severe OA, but it may provide meaningful relief for mild-to-moderate cases with a strong safety advantage.

Toguchi et al. 2023 (PMID 37447322) extended the evidence to a more general population. This Japanese trial randomized 88 healthy adults with mild, non-diagnostic knee discomfort to 2,000 mg/day of MSM (10 tablets of 200 mg) or placebo for 12 weeks. The primary outcome — total score on the Japanese Knee Osteoarthritis Measure (JKOM) — was significantly better in the MSM group (p = 0.046). The health condition subscale also improved significantly (p = 0.032). Notably, this trial demonstrates efficacy in people without diagnosed arthritis, suggesting MSM may help maintain joint comfort proactively, not just treat established disease.

Exercise Recovery: Oxidative Stress and Inflammation

Withee et al. 2017 (PMID 28736511) conducted a randomized, double-blind, placebo-controlled trial embedded in the Portland Half-Marathon. Twenty-two adults (mean age 33.7 years) were randomized to MSM 3 g/day or placebo for 21 days before the race and two days after. Serum was analyzed for oxidative stress markers (8-OHdG, MDA) and muscle damage markers (creatine kinase, lactate dehydrogenase). Both groups showed expected post-race increases in oxidative stress and muscle damage — MSM did not significantly blunt these elevations. However, MSM supplementation was associated with reduced post-race muscle and joint pain at clinically meaningful (though not statistically significant) levels, likely due to the modest sample size. The study was well-controlled but underpowered; a larger trial would be needed to confirm the pain attenuation finding.

van der Merwe and Bloomer 2016 (PMID 27844051) used an interesting design: physically active men supplemented with MSM 3 g/day or placebo for 28 days, then performed 100 eccentric knee extension repetitions (a reliable protocol for inducing delayed onset muscle soreness). Blood was analyzed for cytokines before exercise and at multiple time points up to 72 hours post-exercise. Key findings: LPS-stimulated whole blood cultures from MSM-treated participants showed decreased IL-1β production at rest, suggesting a mildly anti-inflammatory baseline state. After exercise, the MSM group maintained a robust IL-6 and TNF-α response (important for muscle repair) while the placebo group showed a blunted response, suggesting MSM preserved the immune system's adaptive capacity. Additionally, MSM was associated with an acute post-exercise increase in IL-10, an anti-inflammatory cytokine. The picture that emerges is nuanced: MSM does not simply suppress inflammation but appears to modulate the inflammatory response — reducing resting-state inflammatory tone while preserving the exercise-adaptive immune response.

Mechanism: NF-κB and Antioxidant Pathways

The molecular basis for MSM's effects converges on two pathways: NF-κB inhibition and glutathione support. Cell and animal studies consistently show that MSM downregulates NF-κB nuclear translocation, reducing transcription of inflammatory genes. Separately, MSM provides bioavailable sulfur for glutathione synthesis — the tripeptide antioxidant essential for neutralizing reactive oxygen species in joints and muscle tissue. These complementary mechanisms may explain why MSM shows benefits in both chronic inflammatory conditions (arthritis) and acute oxidative contexts (exercise recovery).

Overall Evidence Assessment

MSM has a well-established, if modest, evidence base. The most consistent and reproducible finding is reduction of pain and improvement in physical function in mild-to-moderate knee osteoarthritis, supported by multiple independent RCTs. Effect sizes are real but not dramatic — patients should expect meaningful improvement in discomfort, not complete relief. The exercise recovery evidence is more mixed, with the 2017 half-marathon trial failing to show significant changes in objective oxidative biomarkers but suggesting subjective pain benefits. The anti-inflammatory mechanism is biologically plausible and supported by cell culture and in vivo data. Safety across all trials is excellent. MSM occupies a reasonable position in a joint health protocol, particularly for those seeking non-pharmaceutical options for chronic joint discomfort.